PLYX

$5.54-0.11 (-1.95%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders.

Overview Intraday AnalysisPRO IntelligencePRO Ask AIPRO TranscriptsPRO StatementsPRO

Recent News

TipRanks

Feb 4, 2026

Polaryx to present late-breaker data related to Soteria ahead of trial

Polaryx (PLYX) Therapeutics announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease at the 22nd Annual WORLDSymposium, held February 2-6, 2026 in San Diego, Calif. These data support the continued advancement on progressing the launch of the Soteria trial, a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of PLX-200, in CLN2, CLN3, Krabbe disease, and

BULLISH

Positive press. Headlines skewed toward growth and analyst upgrades.